r-112

R112 是 ATP 竞争性的 Syk 激酶抑制剂，它能够抑制 Syk 激酶活性，Ki=6 nM，IC50=226 nM。

GR-112000 is a peptide-based tachykinin NK2 receptor antagonist.

DBPR112 是一种口服有效的基于氟嘧啶的 EGFR 抑制剂，对 EGFRWT 和 EGFRL858R/T790M 的 IC50 分别为 15 nM 和 48 nM。DBPR112 可以占据 ATP 结合位点。DBPR112 具有显着的抗肿瘤功效。

SR11237 是一种泛视黄醇 X 受体 (RXR) 激动剂。 SR11237 导致 RXR/RXR 同源二聚体形成并反式激活包含 RXR 反应元件的报告基因。

(12aR)-1,12-Bis(diphenylphosphino)-6,7-dihydrodibenzo[e,g][1,4]dioxocine 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T67395。

DBPR112 is a potent EGFR inhibitor (IC50=487 nM) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. DBPR112), DBPR112 not only displayed a potent inhibitory activity against EGFRL858R/T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib,against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidate optimization yielded fourfold oral AUC better that afatinib along with F = 41.5%, an encouraging safety profile, and significant antitumor efficacy in in vivo xenograft models.

Berupipam is a dopamine D1 receptor antagonist.

UR-144, a synthetic cannabinoid, exhibits high affinity for the peripheral cannabinoid receptor (CB2) with a Ki of 1.8 nM, markedly greater than its affinity for the central cannabinoid receptor (CB1), for which it has a Ki of 150 nM. XLR-11 differs from UR-144 by featuring a fluorine atom on the terminal carbon of the alkyl chain and a methyl group on the C2 carbon of the indole. The specific biological activities of XLR-11 remain uncharacterized. It is designed for forensic and research use only.

SR11254-CoA (SR11254-coenzyme A) 是辅酶 A 的一种衍生物。

Histone H2B (108-125) is a peptide fragment of histone H2B that corresponds to amino acid residues 109-126 of the human histone H2B sequence. It contains an N-terminal biotinylated lysine followed by a tryptophan linker. Histone H2B can be modified by addition of an O-linked N-acetylglucosamine (GlcNAc) moiety to the serine residue at position 112, which promotes monoubiquitination of the lysine at position 120.1 Both of these modifications are associated with active transcription. Histone H2B also has lysine residues at positions 108, 116, and 120 that are subject to acetylation.2References1. Fujiki, R., Hashiba, W., Sekine, H., et al. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 480(7378), 557-560 (2011).2. Portela, A., and Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057-1068 (2010). Histone H2B (108-125) is a peptide fragment of histone H2B that corresponds to amino acid residues 109-126 of the human histone H2B sequence. It contains an N-terminal biotinylated lysine followed by a tryptophan linker. Histone H2B can be modified by addition of an O-linked N-acetylglucosamine (GlcNAc) moiety to the serine residue at position 112, which promotes monoubiquitination of the lysine at position 120.1 Both of these modifications are associated with active transcription. Histone H2B also has lysine residues at positions 108, 116, and 120 that are subject to acetylation.2 References1. Fujiki, R., Hashiba, W., Sekine, H., et al. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 480(7378), 557-560 (2011).2. Portela, A., and Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057-1068 (2010).

Pseurotin A has immunosuppressive activity, it inhibits immunoglobulin E(IgE) production in vitro.It shows a moderate effect against the phytopathogenic bacteria Erwinia carotovora and Pseudomonas syringae, with IC50 values of 220 and 112 microg ml(-1), r